Hospitals | April 08, 2026
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Mindset disagrees with and denies the allegations set forth from Reunion.
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Subscribe To Our Newsletter & Stay Updated
